159 related articles for article (PubMed ID: 23948749)
21. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
[TBL] [Abstract][Full Text] [Related]
22. Copy number aberrations in benign serous ovarian tumors: a case for reclassification?
Hunter SM; Anglesio MS; Sharma R; Gilks CB; Melnyk N; Chiew YE; deFazio A; ; Longacre TA; Huntsman DG; Gorringe KL; Campbell IG
Clin Cancer Res; 2011 Dec; 17(23):7273-82. PubMed ID: 21976534
[TBL] [Abstract][Full Text] [Related]
23. Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary.
Lin DI; Killian JK; Venstrom JM; Ramkissoon SH; Ross JS; Elvin JA
Mod Pathol; 2021 May; 34(5):983-993. PubMed ID: 33077920
[TBL] [Abstract][Full Text] [Related]
24. BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.
Wong KK; Tsang YT; Deavers MT; Mok SC; Zu Z; Sun C; Malpica A; Wolf JK; Lu KH; Gershenson DM
Am J Pathol; 2010 Oct; 177(4):1611-7. PubMed ID: 20802181
[TBL] [Abstract][Full Text] [Related]
25. Morphometry and digital AgNOR analysis in cytological imprints of benign, borderline and malignant serous ovarian tumours.
Stemberger-Papić S; Stanković T; Vrdoljak-Mozetic D; Versa-Ostojić D; Krasević M; Stifter S; Audy-Jurković S
Cytopathology; 2006 Dec; 17(6):382-9. PubMed ID: 17168922
[TBL] [Abstract][Full Text] [Related]
26. Changes in gene expression during progression of ovarian carcinoma.
Tapper J; Kettunen E; El-Rifai W; Seppälä M; Andersson LC; Knuutila S
Cancer Genet Cytogenet; 2001 Jul; 128(1):1-6. PubMed ID: 11454421
[TBL] [Abstract][Full Text] [Related]
27. The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer.
King ER; Tung CS; Tsang YT; Zu Z; Lok GT; Deavers MT; Malpica A; Wolf JK; Lu KH; Birrer MJ; Mok SC; Gershenson DM; Wong KK
Am J Surg Pathol; 2011 Jun; 35(6):904-12. PubMed ID: 21451362
[TBL] [Abstract][Full Text] [Related]
28. Gene expression profiles in three histologic types, clear-cell, endometrioid and serous ovarian carcinomas.
Pamuła-Piłat J; Rubel T; Rzepecka IK; Olbryt M; Herok R; Dansonka-Mieszkowska A; Grzybowska E; Kupryjańczyk J
J Biol Regul Homeost Agents; 2014; 28(4):659-74. PubMed ID: 25620176
[TBL] [Abstract][Full Text] [Related]
29. KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome.
Zuo T; Wong S; Buza N; Hui P
Mod Pathol; 2018 Feb; 31(2):350-357. PubMed ID: 29027536
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of MTAP immunohistochemistry loss of expression in ovarian serous borderline tumors as a potential marker for prognosis and progression.
Nilforoushan N; Moatamed NA
Ann Diagn Pathol; 2020 Oct; 48():151582. PubMed ID: 32866902
[TBL] [Abstract][Full Text] [Related]
31. Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges.
Shih IeM; Kurman RJ
Clin Cancer Res; 2005 Oct; 11(20):7273-9. PubMed ID: 16243797
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathological significance of DEK overexpression in serous ovarian tumors.
Han S; Xuan Y; Liu S; Zhang M; Jin D; Jin R; Lin Z
Pathol Int; 2009 Jul; 59(7):443-7. PubMed ID: 19563407
[TBL] [Abstract][Full Text] [Related]
33. Pattern of HER-2 Gene Amplification and Protein Expression in Benign, Borderline, and Malignant Ovarian Serous and Mucinous Neoplasms.
Mohammed RAA; Makboul R; Elsers DAH; Elsaba TMAM; Thalab AMAB; Shaaban OM
Int J Gynecol Pathol; 2017 Jan; 36(1):50-57. PubMed ID: 27309616
[TBL] [Abstract][Full Text] [Related]
34. [K-ras mutation analysis in ovarian serous borderline and malignant tumors].
Ma L; Guo LN; Liang ZY; Ren XY; Wu SF
Zhonghua Bing Li Xue Za Zhi; 2006 Dec; 35(12):714-8. PubMed ID: 17374253
[TBL] [Abstract][Full Text] [Related]
35. Progressive loss of selenium-binding protein 1 expression correlates with increasing epithelial proliferation and papillary complexity in ovarian serous borderline tumor and low-grade serous carcinoma.
Zhang C; Wang YE; Zhang P; Liu F; Sung CJ; Steinhoff MM; Quddus MR; Lawrence WD
Hum Pathol; 2010 Feb; 41(2):255-61. PubMed ID: 19896693
[TBL] [Abstract][Full Text] [Related]
36. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion.
McKenney JK; Balzer BL; Longacre TA
Am J Surg Pathol; 2006 Oct; 30(10):1209-21. PubMed ID: 17001150
[TBL] [Abstract][Full Text] [Related]
37. Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling.
Gilks CB; Vanderhyden BC; Zhu S; van de Rijn M; Longacre TA
Gynecol Oncol; 2005 Mar; 96(3):684-94. PubMed ID: 15721412
[TBL] [Abstract][Full Text] [Related]
38. Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE).
Talhouk A; George J; Wang C; Budden T; Tan TZ; Chiu DS; Kommoss S; Leong HS; Chen S; Intermaggio MP; Gilks B; Nazeran TM; Volchek M; Elatre W; Bentley RC; Senz J; Lum A; Chow V; Sudderuddin H; Mackenzie R; Leong SCY; Liu G; Johnson D; Chen B; Group A; Alsop J; Banerjee SN; Behrens S; Bodelon C; Brand AH; Brinton L; Carney ME; Chiew YE; Cushing-Haugen KL; Cybulski C; Ennis D; Fereday S; Fortner RT; García-Donas J; Gentry-Maharaj A; Glasspool R; Goranova T; Greene CS; Haluska P; Harris HR; Hendley J; Hernandez BY; Herpel E; Jimenez-Linan M; Karpinskyj C; Kaufmann SH; Keeney GL; Kennedy CJ; Köbel M; Koziak JM; Larson MC; Lester J; Lewsley LA; Lissowska J; Lubiński J; Luk H; Macintyre G; Mahner S; McNeish IA; Menkiszak J; Nevins N; Osorio A; Oszurek O; Palacios J; Hinsley S; Pearce CL; Pike MC; Piskorz AM; Ray-Coquard I; Rhenius V; Rodriguez-Antona C; Sharma R; Sherman ME; De Silva D; Singh N; Sinn P; Slamon D; Song H; Steed H; Stronach EA; Thompson PJ; Tołoczko A; Trabert B; Traficante N; Tseng CC; Widschwendter M; Wilkens LR; Winham SJ; Winterhoff B; Beeghly-Fadiel A; Benitez J; Berchuck A; Brenton JD; Brown R; Chang-Claude J; Chenevix-Trench G; deFazio A; Fasching PA; García MJ; Gayther SA; Goodman MT; Gronwald J; Henderson MJ; Karlan BY; Kelemen LE; Menon U; Orsulic S; Pharoah PDP; Wentzensen N; Wu AH; Schildkraut JM; Rossing MA; Konecny GE; Huntsman DG; Huang RY; Goode EL; Ramus SJ; Doherty JA; Bowtell DD; Anglesio MS
Clin Cancer Res; 2020 Oct; 26(20):5411-5423. PubMed ID: 32554541
[TBL] [Abstract][Full Text] [Related]
39. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract][Full Text] [Related]
40. KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.
Tsang YT; Deavers MT; Sun CC; Kwan SY; Kuo E; Malpica A; Mok SC; Gershenson DM; Wong KK
J Pathol; 2013 Dec; 231(4):449-56. PubMed ID: 24549645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]